58 related articles for article (PubMed ID: 24570330)
1. Phase II clinical trial of PM00104 (Zalypsis(®)) in urothelial carcinoma patients progressing after first-line platinum-based regimen.
Castellano DE; Bellmunt J; Maroto JP; Font-Pous A; Morales-Barrera R; Ghanem I; Suarez C; Martín Lorente C; Etxaniz O; Capdevila L; Coronado C; Alfaro V; Siguero M; Fernández-Teruel C; Carles J
Cancer Chemother Pharmacol; 2014 Apr; 73(4):857-67. PubMed ID: 24570330
[TBL] [Abstract][Full Text] [Related]
2. A phase I pharmacokinetic study of PM00104 (Zalypsis) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors.
Capdevila J; Clive S; Casado E; Michie C; Piera A; Sicart E; Carreras MJ; Coronado C; Kahatt C; Soto Matos-Pita A; Fernandez Teruel C; Siguero M; Cullell-Young M; Tabernero J
Cancer Chemother Pharmacol; 2013 May; 71(5):1247-54. PubMed ID: 23455428
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of carboplatin in combination with PM00104 (Zalypsis®) in patients with advanced solid tumors.
Salazar R; Calles A; Gil M; Durán I; García M; Hidalgo M; Coronado C; Alfaro V; Siguero M; Fernández-Teruel C; Prados R; Calvo E
Invest New Drugs; 2014 Aug; 32(4):644-52. PubMed ID: 24535315
[TBL] [Abstract][Full Text] [Related]
4. Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy.
Galsky MD; Seng S; Camacho LH; Chiorean EG; Mulkerin D; Hong DS; Oh WK; Bajorin DF
Clin Genitourin Cancer; 2011 Sep; 9(1):27-30. PubMed ID: 21700509
[TBL] [Abstract][Full Text] [Related]
5. First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours.
Yap TA; Cortes-Funes H; Shaw H; Rodriguez R; Olmos D; Lal R; Fong PC; Tan DS; Harris D; Capdevila J; Coronado C; Alfaro V; Soto-Matos A; Fernández-Teruel C; Siguero M; Tabernero JM; Paz-Ares L; de Bono JS; López-Martin JA
Br J Cancer; 2012 Apr; 106(8):1379-85. PubMed ID: 22491421
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of PM00104 (Zalypsis(®)) in cancer patients.
Pérez-Ruixo C; Valenzuela B; Fernández Teruel C; González-Sales M; Miguel-Lillo B; Soto-Matos A; Pérez-Ruixo JJ
Cancer Chemother Pharmacol; 2012 Jan; 69(1):15-24. PubMed ID: 21590449
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of weekly paclitaxel and carboplatin chemotherapy in patients with advanced transitional cell cancer.
Johannsen M; Sachs M; Roigas J; Hinke A; Staack A; Loening SA; Schnorr D; Wille AH
Eur Urol; 2005 Aug; 48(2):246-51. PubMed ID: 15963636
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors.
Massard C; Margetts J; Amellal N; Drew Y; Bahleda R; Stephens P; Armand JP; Calvert H; Soria JC; Coronado C; Kahatt C; Alfaro V; Siguero M; Fernández-Teruel C; Plummer R
Invest New Drugs; 2013 Jun; 31(3):623-30. PubMed ID: 22688291
[TBL] [Abstract][Full Text] [Related]
9. Weekly regimen of epirubicin and paclitaxel as second-line chemotherapy in patients with metastatic transitional cell carcinoma of urothelial tract: results of a phase II study.
Rozzi A; Salerno M; Bordin F; De Marco F; Di Nicola S; Lanzetta G
Med Oncol; 2011 Dec; 28 Suppl 1():S426-32. PubMed ID: 21116878
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study.
Vaishampayan UN; Faulkner JR; Small EJ; Redman BG; Keiser WL; Petrylak DP; Crawford ED
Cancer; 2005 Oct; 104(8):1627-32. PubMed ID: 16138364
[TBL] [Abstract][Full Text] [Related]
11. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium.
Dreicer R; Manola J; Roth BJ; See WA; Kuross S; Edelman MJ; Hudes GR; Wilding G
Cancer; 2004 Apr; 100(8):1639-45. PubMed ID: 15073851
[TBL] [Abstract][Full Text] [Related]
12. Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy.
Gerullis H; Eimer C; Ecke TH; Georgas E; Arndt C; Otto T
Anticancer Drugs; 2013 Apr; 24(4):422-5. PubMed ID: 23407060
[TBL] [Abstract][Full Text] [Related]
13. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Experience from an Expanded Access Study in the United States.
Pal SK; Hoffman-Censits J; Zheng H; Kaiser C; Tayama D; Bellmunt J
Eur Urol; 2018 May; 73(5):800-806. PubMed ID: 29478735
[TBL] [Abstract][Full Text] [Related]
14. Phase II open-label study of oral piritrexim in patients with advanced carcinoma of the urothelium who have experienced failure with standard chemotherapy.
Lassiter LK; Tummala MK; Hussain MH; Stadler WM; Petrylak DP; Carducci MA
Clin Genitourin Cancer; 2008 Mar; 6(1):31-5. PubMed ID: 18501080
[TBL] [Abstract][Full Text] [Related]
15. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ
Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
[TBL] [Abstract][Full Text] [Related]
16. A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma.
Pond GR; Agarwal N; Bellmunt J; Choueiri TK; Qu A; Fougeray R; Vaughn D; James ND; Salhi Y; Albers P; Niegisch G; Galsky MD; Wong YN; Ko YJ; Stadler WM; O'Donnell PH; Sridhar SS; Vogelzang NJ; Necchi A; Di Lorenzo G; Sternberg CN; Mehta A; Sonpavde G
BJU Int; 2014 May; 113(5b):E137-43. PubMed ID: 24219029
[TBL] [Abstract][Full Text] [Related]
17. Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules.
Bajorin DF; McCaffrey JA; Dodd PM; Hilton S; Mazumdar M; Kelly WK; Herr H; Scher HI; Icasiano E; Higgins G
Cancer; 2000 Apr; 88(7):1671-8. PubMed ID: 10738226
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel Carboplatin chemotherapy as a second-line chemotherapy for advanced platinum resistant urothelial cancer in Japanese cases.
Soga N; Onishi T; Arima K; Sugimura Y
Int J Urol; 2007 Sep; 14(9):828-32. PubMed ID: 17760750
[TBL] [Abstract][Full Text] [Related]
19. [Clinical study of combination chemotherapy of methotrexate, epirubicin and nedaplatin (MEN) in patients with advanced urothelial carcinoma].
Hattori Y; Takizawa A; Kishida T; Kakizoe M; Fujikawa N; Teranishi J; Kondo K; Saito K; Noguchi K; Nakaigawa N; Kubota Y
Gan To Kagaku Ryoho; 2007 May; 34(5):739-43. PubMed ID: 17496448
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma.
Galsky MD; Hahn NM; Wong B; Lee KM; Argiriadi P; Albany C; Gimpel-Tetra K; Lowe N; Shahin M; Patel V; Tsao CK; Oh WK
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1259-65. PubMed ID: 26464352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
